CF Drug's hidden effects: study probes metabolism and microbiome changes
NCT ID NCT07363304
First seen Feb 02, 2026 · Last updated May 11, 2026 · Updated 11 times
Summary
This study looks at how the cystic fibrosis drug combination ETI (elexacaftor-tezacaftor-ivacaftor) affects metabolism, gene activity, and gut bacteria in 150 people with CF. Researchers want to understand why some patients develop side effects like high cholesterol or obesity. The goal is to find ways to personalize dosing and reduce long-term risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedaliera Universitaria Meyer Istituto di Ricovero e Cura a Carattere Scientifico
RECRUITINGFlorence, 5016, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centro per la Fibrosi Cistica, Azienda Universitaria Ospedaliera Consorziale Policlinico
NOT_YET_RECRUITINGBari, Bari, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centro per la Fibrosi Cistica, Ospedale Infantile Regina Margherita
NOT_YET_RECRUITINGTorino, Torino, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dipartimento di Pediatria, Centro Fibrosi Cistica, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
NOT_YET_RECRUITINGMilan, Milano, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ospedale pediatrico Bambino Gesù, IRCCS, Dipartimento Pediatrico Universitario Ospedaliero, UOC Pneumologia e Fibrosi Cistica
NOT_YET_RECRUITINGRoma, Roma, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Unità Pediatrica, Dipartimento di Scienze Mediche Traslazionali, Centro di Riferimento Regionale per la Fibrosi Cistica, Università degli Studi di Napoli Federico II
NOT_YET_RECRUITINGNaples, Napoli, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.